RT Journal Article
SR Electronic
T1 Synthetic Lethality-based Targets for Discovery of New Cancer Therapeutics
JF Cancer Genomics - Proteomics
JO Cancer Genomics Proteomics
FD International Institute of Anticancer Research
SP 159
OP 171
VO 8
IS 4
A1 Ulrich H. Weidle
A1 Daniela Maisel
A1 Dirk Eick
YR 2011
UL http://cgp.iiarjournals.org/content/8/4/159.abstract
AB Synthetic lethality is based on the incompatibility of cell survival with the loss of function of two or more genes, not with loss of function of a single gene. If targets of synthetic lethality are deregulated or mutated in cancer cells, the strategy of synthetic lethality can result in significant increase of therapeutic efficacy and a favourable therapeutic window. In this review, we discuss synthetic lethality based on deficient DNA repair mechanisms, activating mutations of RAS, loss of function mutations of the tumor suppressor genes p53, Rb and von Hippel-Lindau, and disruption of interactive protein kinase networks in the context of development of new anticancer agents.